Abstract 124P
Background
BRAF V600E is identified approximately 5-9% of colorectal cancer (CRC) patients. Non-V600E BRAF mutation is characterized a rare molecular subtype. The clinical characteristics and prognostic impact of non-V600 BRAF mutants are not well defined.
Methods
We recruited 829 patients with CRC from our institution. Tissue samples were molecularly tested. Clinical data was retrospectively reviewed and analyzed using Chi-square and t-test. Overall survival (OS) was compared by log-rank test.
Results
All BRAF mutation was detected in 50 (6%) patients including 24 (3%) patients with non-V600 mutations. Patient characteristics and BRAF testing technique were not significantly different based on BRAF status and it was comparable between BRAF V600E and non-V600 groups. There were significantly more ALL RAS and PIK3CA mutations in non-V600 mutant patients. Patients with non-V600 mutation had median OS of 82 months which was longer than BRAF WT, 66 months, and 31 months of BRAF V600E group, respectively (P=0.067). OS according to treatment with anti-EGFR in metastatic CRC patients was not significantly different in both V600E and non-V600 BRAF mutant groups. Table: 124P
BRAF-MT (n=50) | |||||||
BRAF-WT (n=779) | BRAF-MT (n=50) | p-value | V600 (n=26) | non-V600 (n=24) | p-value | ||
Age | 63 (18 - 93) | 65 (19-85) | 66 (19 - 85) | 65 (24 - 83) | |||
Sex | |||||||
Male | 471 (60) | 32 (64) | 0.62 | 15 (58) | 17 (71) | 0.333 | |
Female | 308 (40) | 18 (36) | 11 (42) | 7 (29) | |||
Sidedness | |||||||
Left | 591 (76) | 33 (66) | 0.289 | 12 (70) | 15 (62) | 0.878 | |
Right | 168 (22) | 15 (30) | 7 (27) | 8 (33) | |||
non-specify | 20 (3) | 2 (4) | 1 (4) | 1 (4) | |||
Technique | |||||||
NGS | 547 (70) | 38 (76) | 0.466 | 18 (69) | 20 (83) | 0.26 | |
Pyrosequencing | 84 (11) | 6 (12) | 5 (19) | 1 (4) | |||
PCR | 148 (19) | 6 (12) | 3 (12) | 2 (12) | |||
All RAS mutation | 418 (54) | 8 (16) | <0.001 | 0 | 8 (33) | 0.001 | |
PIK3CA mutation | 94 (12) | 9 (18) | 0.218 | 1 (4) | 8 (33) | 0.009 | |
Recur/Met | (n=575) | (n=35) | (n=19) | (n=16) | |||
Anti-VEGF | 105 (18) | 7 (20) | 0.796 | 2 (11) | 5 (31) | 0.207 | |
Anti-EGFR | 162 (28) | 6 (17) | 0.156 | 3 (16) | 3 (19) | 1 |
Conclusions
Non-V600 BRAF mutation may indicate better prognosis. The difference in treatment effect was not demonstrated in patients with BRAF mutation.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Faculty of medicine Ramathibodi Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract
163P - Chemotherapy versus palliative radiotherapy in advanced inoperable gall bladder cancer
Presenter: Vimal Sekar
Session: Poster Display
Resources:
Abstract